### Contents

#### VIEWPOINT

**159** Bath Salts to Therapies: Can Separation of Adverse and Therapeutic Effects of Substituted Cathinones Lead to a Medication for Psychostimulant Use Disorder?
*Ellen M. Unterwald and Scott M. Rawls*

**162** Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in Rats
*Michael R. Chojnacki, Eric B. Thorndike, John S. Partilla, Kenner C. Rice, Charles W. Schindler, and Michael H. Baumann*

#### BEHAVIORAL PHARMACOLOGY

**171** Assessment of Abuse-Related Discriminative Stimulus Effects of Nicotine Aerosol in Rodents
*Yasmin Alkhlaif and Keith L. Shelton*

**180** Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats
*Shyam H. Kamble, Samuel Obeng, Francisco León, Luis F. Restrepo, Tamara I. King, Erin C. Berthold, Siva Rama Raju Kanumuri, Lea R. Gámez-Jiménez, Victoria L.C. Pallares, Avi Patel, Nicholas P. Ho, Aidan Hampson, Christopher R. McCurdy, Lance R. McMahon, Jenny L. Wilkerson, Abhisheak Sharma, and Takato Hiranita*

#### DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

**193** TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy
*Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, Kimio Tohyama, Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, and Haruhide Kimura*

**205** In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule *ent*-Verticilide
*Daniel J. Blackwell, Abigail N. Smith, Tri Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R. Hopkins, Wendell S. Akers, Jeffrey N. Johnston, and Bjorn C. Knollmann*

#### ENDOCRINE AND DIABETES

**214** BI-Y, an Neuropilin-1 Antagonist, Enhances Revascularization and Prevents Vascular Endothelial Growth Factor-A Induced Retinal Hyperpermeability in Rodent Models of Retinopathies
*Leo Thomas, Sarah Low, Gale Hansen, Remko A. Bakker, and Nina Zippel*

#### ERRATUM

Correction to “Cannabinoid Tolerance in S426A/S430A x β-Arrestin 2 Knockout Double-Mutant Mice”
*Supplemental material is available at jpet.aspetjournals.org.*

*About the cover: BI-Y antagonizes the biological effects of Nrp-1, thus also Sema3A and partially VEGF, promoting revascularization and reducing hyperpermeability. See the article by Thomas et al. (dx.doi.org/10.1124/jpet.122.001473).*